Table 5 CTLA-4 and IL-6 co-existing genotypes, along with their relative risk, odds ratio and p-value in HCV-induced HCC patients
From: Association of CTLA-4 and IL-4 polymorphisms in viral induced liver cancer
Genotype (CTLA4 + IL6) | Number | Relative Risk (95% CI) | Odds Ratio (95% CI) | P-value | |
|---|---|---|---|---|---|
Patients (%) | Control (%) | ||||
GG + TT | 11 (5.16%) | 14 (6.48%) | 0.88 (0.52—1.28) | 0.78 (0.35—1.71) | 0.68 |
GG + TC | 25 (11.74%) | 107 (48.61%) | 0.31 (0.21—0.43) | 0.140 (0.085—0.23) |  < 0.0001 |
GG + CC | 43 (20.19%) | 40 (18.52%) | 1.05 (0.82—1.31) | 1.113 (0.68—1.81) | 0.71 |
GA + TT | 18 (8.45%) | 6 (2.91%) | 1.51 (1.10—1.85) | 3.077 (1.26—7.56) | 0.01 |
GA + TC | 21 (9.86%) | 29 (13.43%) | 0.82 (0.57—1.12) | 0.7053 (0.39—1.27) | 0.29 |
GA + CC | 95 (44.60%) | 20 (9.26%) | 2.19 (1.86—2.59) | 7.890 (4.63—13.72) |  < 0.0001 |